Literature DB >> 20498327

Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components.

Danuta Tomkiewicz1, Gabriele Casadei, Jonah Larkins-Ford, Terence I Moy, James Garner, John B Bremner, Frederick M Ausubel, Kim Lewis, Michael J Kelso.   

Abstract

Hybrid antimicrobials containing an antibacterial linked to a multidrug resistance (MDR) pump inhibitor make up a promising new class of agents for countering efflux-mediated bacterial drug resistance. This study explores the effects of varying the relative orientation of the antibacterial and efflux pump inhibitor components in three isomeric hybrids (SS14, SS14-M, and SS14-P) which link the antibacterial alkaloid and known substrate for the NorA MDR pump berberine to different positions on INF55 (5-nitro-2-phenylindole), an inhibitor of NorA. The MICs for all three hybrids against wild-type, NorA-knockout, and NorA-overexpressing Staphylococcus aureus cells were found to be similar (9.4 to 40.2 microM), indicating that these compounds are not effectively effluxed by NorA. The three hybrids were also found to have similar curing effects in a Caenorhabditis elegans live infection model. Each hybrid was shown to accumulate in S. aureus cells to a greater extent than either berberine or berberine in the presence of INF55, and the uptake kinetics of SS14 were found to differ from those of SS14-M and SS14-P. The effects on the uptake and efflux of the NorA substrate ethidium bromide into S. aureus cells in the presence or absence of the hybrids were used to confirm MDR inhibition by the hybrids. MDR-inhibitory activity was confirmed for SS14-M and SS14-P but not for SS14. Molecular dynamics simulations revealed that SS14 prefers to adopt a conformation that is not prevalent in either SS14-M or SS14-P, which may explain why some properties of SS14 diverge from those of its two isomers. In summary, subtle repositioning of the pump-blocking INF55 moiety in berberine-INF55 hybrids was found to have a minimal effect on their antibacterial activities but to significantly alter their effects on MDR pumps.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498327      PMCID: PMC2916310          DOI: 10.1128/AAC.01715-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  SEK-1 MAPKK mediates Ca2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans.

Authors:  Miho Tanaka-Hino; Alvaro Sagasti; Naoki Hisamoto; Masato Kawasaki; Shunji Nakano; Jun Ninomiya-Tsuji; Cornelia I Bargmann; Kunihiro Matsumoto
Journal:  EMBO Rep       Date:  2001-12-19       Impact factor: 8.807

Review 2.  Unmet medical needs in antibacterial therapy.

Authors:  Louis B Rice
Journal:  Biochem Pharmacol       Date:  2005-11-08       Impact factor: 5.858

3.  Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial.

Authors:  Anthony R Ball; Gabriele Casadei; Siritron Samosorn; John B Bremner; Frederick M Ausubel; Terence I Moy; Kim Lewis
Journal:  ACS Chem Biol       Date:  2006-10-24       Impact factor: 5.100

Review 4.  Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

Authors:  Olga Lomovskaya; Keith A Bostian
Journal:  Biochem Pharmacol       Date:  2006-01-19       Impact factor: 5.858

5.  Microbes have the last word. A drastic re-evaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria.

Authors:  Julian Davies
Journal:  EMBO Rep       Date:  2007-07       Impact factor: 8.807

6.  Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.

Authors:  Nadezhda German; Peng Wei; Glenn W Kaatz; Robert J Kerns
Journal:  Eur J Med Chem       Date:  2008-02-08       Impact factor: 6.514

Review 7.  Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.

Authors:  Patrice Nordmann; Thierry Naas; Nicolas Fortineau; Laurent Poirel
Journal:  Curr Opin Microbiol       Date:  2007-08-30       Impact factor: 7.934

8.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.

Authors:  A A Neyfakh; C M Borsch; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group.

Authors:  Siritron Samosorn; Bongkot Tanwirat; Nussara Muhamad; Gabriele Casadei; Danuta Tomkiewicz; Kim Lewis; Apichart Suksamrarn; Therdsak Prammananan; Karina C Gornall; Jennifer L Beck; John B Bremner
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

10.  Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus.

Authors:  Jianzhong Huang; Paul W O'Toole; Wei Shen; Heather Amrine-Madsen; Xinhe Jiang; Neethan Lobo; Leslie M Palmer; LeRoy Voelker; Frank Fan; Michael N Gwynn; Damien McDevitt
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  10 in total

Review 1.  Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes.

Authors:  Domingo Mariano Adolfo Vera; Mark H Haynes; Anthony R Ball; Tianhong Dai; Christos Astrakas; Michael J Kelso; Michael R Hamblin; George P Tegos
Journal:  Photochem Photobiol       Date:  2012-02-13       Impact factor: 3.421

2.  Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis).

Authors:  Hiyas A Junio; Arlene A Sy-Cordero; Keivan A Ettefagh; Johnna T Burns; Kathryn T Micko; Tyler N Graf; Scott J Richter; Robert E Cannon; Nicholas H Oberlies; Nadja B Cech
Journal:  J Nat Prod       Date:  2011-06-10       Impact factor: 4.050

3.  Attaching the NorA Efflux Pump Inhibitor INF55 to Methylene Blue Enhances Antimicrobial Photodynamic Inactivation of Methicillin-Resistant Staphylococcus aureus in Vitro and in Vivo.

Authors:  Ardeshir Rineh; Naveen K Dolla; Anthony R Ball; Maria Magana; John B Bremner; Michael R Hamblin; George P Tegos; Michael J Kelso
Journal:  ACS Infect Dis       Date:  2017-08-17       Impact factor: 5.084

Review 4.  Caenorhabditis elegans-based model systems for antifungal drug discovery.

Authors:  Cleo G Anastassopoulou; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 5.  Microbial efflux pump inhibition: tactics and strategies.

Authors:  George P Tegos; Mark Haynes; J Jacob Strouse; Mohiuddin Md T Khan; Cristian G Bologa; Tudor I Oprea; Larry A Sklar
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  On the Mechanism of Berberine-INF55 (5-Nitro-2-phenylindole) Hybrid Antibacterials.

Authors:  Naveen K Dolla; Chao Chen; Jonah Larkins-Ford; Rajmohan Rajamuthiah; Sakthimala Jagadeesan; Annie L Conery; Frederick M Ausubel; Eleftherios Mylonakis; John B Bremner; Kim Lewis; Michael J Kelso
Journal:  Aust J Chem       Date:  2015       Impact factor: 1.321

Review 7.  Beyond Traditional Antimicrobials: A Caenorhabditis elegans Model for Discovery of Novel Anti-infectives.

Authors:  Cin Kong; Su-Anne Eng; Mei-Perng Lim; Sheila Nathan
Journal:  Front Microbiol       Date:  2016-12-02       Impact factor: 5.640

8.  Synthesis and structural characterization of 1-[2-(5-nitro-1H-indol-2-yl)phenyl]methylpyridinium chloride.

Authors:  John B Bremner; Siritron Samosorn; Brian W Skelton; Allan H White
Journal:  Molecules       Date:  2011-09-06       Impact factor: 4.411

9.  Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation.

Authors:  Christina Kourtesi; Anthony R Ball; Ying-Ying Huang; Sanjay M Jachak; D Mariano A Vera; Proma Khondkar; Simon Gibbons; Michael R Hamblin; George P Tegos
Journal:  Open Microbiol J       Date:  2013-03-22

10.  Uptake of and Resistance to the Antibiotic Berberine by Individual Dormant, Germinating and Outgrowing Bacillus Spores as Monitored by Laser Tweezers Raman Spectroscopy.

Authors:  Shiwei Wang; Jing Yu; Milomir Suvira; Peter Setlow; Yong-qing Li
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.